MarginsXMarginsX
Home › Markets › Health Care › ANIP

ANI Pharmaceuticals Inc. (ANIP)

ANIP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$70.89
-0.77% on the day
Market cap
$1.6B
Small cap
Revenue · 2025
$883.4M
+43.8% on 2024
Net income · 2025
$78.3M
8.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/0001023024-26-000014-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerANIP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001023024
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$883.4M
Net income$78.3M
Operating income$111.1M
Net margin8.9%
Operating margin12.6%
Revenue growth+43.8%
Cash$285.6M
Total assets$1.4B
P/E (computed)20.6×
P/S (computed)1.8×

Warning signs

Cash runway
Cash-flow positive
$420.8M cash at September 30, 2026
Share count, 1 year
+1.2%
2025-10-31 to 2026-10-29
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$15.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$420.8M cash; operating cash flow $57.3M a quarter.Report 2026-09-30
Shares outstanding22,729,795 (2026-10-29); 22,469,032 a year earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEisnerAmper LLP, Iselin, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $15.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$290.8M$35.1M$83.8M$420.8M$297.7M$1.0B10-Q 2026-11-05
Q2 2026
2026-06-30
$266.0M$24.7M$56.7M$360.2M$301.5M$978.4M10-Q 2026-08-07
Q1 2026
2026-03-31
$237.5M$29.5M$58.4M$311.2M$305.3M$923.7M10-Q 2026-05-08
Q4 2025
2025-12-31
$247.1M$27.5M$30.4M$285.6M$309.1M$883.4M10-K 2026-02-27
Q3 2025
2025-09-30
$227.8M$26.6M$44.1M$262.6M$312.9M$826.9M10-Q 2026-11-05
Q2 2025
2025-06-30
$211.4M$8.5M$75.8M$217.8M$314.7M$747.4M10-Q 2026-08-07
Q1 2025
2025-03-31
$197.1M$15.7M$35.0M$149.8M$316.5M$674.1M10-Q 2026-05-08
Q4 2024
2024-12-31
$190.6M-$10.3M$15.9M$144.9M$318.3M$614.4M10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52023-05-12
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-09

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.0%
1 month+0.8%
3 months-4.5%
Year to date-9.5%
1 year-15.5%
From 52-week high-17.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B
SRPTSarepta Therapeutics Inc. Common Stock (DE)$15.13-5.85%$1.6B
KLRAKailera Therapeutics Inc.$12.57-5.28%$1.6B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
PGENPrecigen Inc.$4.30-5.29%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier